Clinical application of genetic testing for sensorineural hearing loss

Peter King, Ariel Grobman, Xue Z Liu

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hearing loss (HL) is the most common sensory disorder, affecting all age groups, ethnicities, and genders. According to World Health Organization (WHO) estimates in 2005, 278 million people worldwide have moderate to profound HL in both ears. Results of the 2002 National Health Interview Survey indicate that nearly 31 million of all non-institutionalized adults (aged 18 and over) in the United States have trouble hearing. Epidemiological studies have estimated that approximately 50% of profound HL can be attributed to genetic causes. With over 60 genes implicated in nonsyndromic hearing loss, it is also an extremely heterogeneous trait. Hearing loss can be acquired or inherited and can also be either syndromic or non-syndromic. Recent progress in identifying genes responsible for hearing loss enables otolaryngologists and other clinicians to apply molecular diagnosis by genetic testing. However, the routine application of these tests is hampered by the large number of genes involved in HL and by the fact that molecular screening of these genes is often quite expensive and time consuming. Only a minority of these genes is currently included in genetic diagnostics. In childhood hearing loss, early educational intervention is required in addition to medical intervention for normal development of speech and language. In addition, even severe to profound hearing loss may be restored very effectively by hearing aids or cochlear implants. Because of these features of sensorineural hearing loss (SNHL), genetic testing has exceptionally high value in the medical practice for hereditary hearing loss. Several strategies are used for genetic testing of SNHL for accurate and efficient identification of the genetic causes, and the results were used for explanation of the cause, prediction of auditory features, prevention of deafness, management of associated symptoms, determination of therapy, and genetic counseling. Implementing new and powerful DNA high throughput sequencing technologies is likely to happen within the next several years, and will cause a breakthrough in terms of power and cost efficiency. This ability will greatly improve DNA diagnostics. This chapter focuses on describing clinical implications of the most frequent genes including GJB2, which is responsible for more than half of cases, followed by SLC26A4, MYO15A, OTOF, CDH23, TMC1, WFS1, MYO7A, and COCH and a cost-effective stepwise diagnostic paradigm for sensorineural hearing loss.

Original languageEnglish
Title of host publicationHearing Loss: Classification, Causes and Treatment
PublisherNova Science Publishers, Inc.
Pages399-410
Number of pages12
ISBN (Print)9781612095080
StatePublished - Apr 1 2011

Fingerprint

Sensorineural Hearing Loss
Genetic Testing
Hearing Loss
Genes
Sensation Disorders
Costs and Cost Analysis
High-Throughput Nucleotide Sequencing
Language Development
Aptitude
Hearing Aids
Cochlear Implants
Genetic Counseling
Deafness
Health Surveys
Hearing
Ear
Epidemiologic Studies
Molecular Biology
Age Groups
Interviews

ASJC Scopus subject areas

  • Medicine(all)

Cite this

King, P., Grobman, A., & Liu, X. Z. (2011). Clinical application of genetic testing for sensorineural hearing loss. In Hearing Loss: Classification, Causes and Treatment (pp. 399-410). Nova Science Publishers, Inc..

Clinical application of genetic testing for sensorineural hearing loss. / King, Peter; Grobman, Ariel; Liu, Xue Z.

Hearing Loss: Classification, Causes and Treatment. Nova Science Publishers, Inc., 2011. p. 399-410.

Research output: Chapter in Book/Report/Conference proceedingChapter

King, P, Grobman, A & Liu, XZ 2011, Clinical application of genetic testing for sensorineural hearing loss. in Hearing Loss: Classification, Causes and Treatment. Nova Science Publishers, Inc., pp. 399-410.
King P, Grobman A, Liu XZ. Clinical application of genetic testing for sensorineural hearing loss. In Hearing Loss: Classification, Causes and Treatment. Nova Science Publishers, Inc. 2011. p. 399-410
King, Peter ; Grobman, Ariel ; Liu, Xue Z. / Clinical application of genetic testing for sensorineural hearing loss. Hearing Loss: Classification, Causes and Treatment. Nova Science Publishers, Inc., 2011. pp. 399-410
@inbook{188449242515402f951bba640d2ca2fb,
title = "Clinical application of genetic testing for sensorineural hearing loss",
abstract = "Hearing loss (HL) is the most common sensory disorder, affecting all age groups, ethnicities, and genders. According to World Health Organization (WHO) estimates in 2005, 278 million people worldwide have moderate to profound HL in both ears. Results of the 2002 National Health Interview Survey indicate that nearly 31 million of all non-institutionalized adults (aged 18 and over) in the United States have trouble hearing. Epidemiological studies have estimated that approximately 50{\%} of profound HL can be attributed to genetic causes. With over 60 genes implicated in nonsyndromic hearing loss, it is also an extremely heterogeneous trait. Hearing loss can be acquired or inherited and can also be either syndromic or non-syndromic. Recent progress in identifying genes responsible for hearing loss enables otolaryngologists and other clinicians to apply molecular diagnosis by genetic testing. However, the routine application of these tests is hampered by the large number of genes involved in HL and by the fact that molecular screening of these genes is often quite expensive and time consuming. Only a minority of these genes is currently included in genetic diagnostics. In childhood hearing loss, early educational intervention is required in addition to medical intervention for normal development of speech and language. In addition, even severe to profound hearing loss may be restored very effectively by hearing aids or cochlear implants. Because of these features of sensorineural hearing loss (SNHL), genetic testing has exceptionally high value in the medical practice for hereditary hearing loss. Several strategies are used for genetic testing of SNHL for accurate and efficient identification of the genetic causes, and the results were used for explanation of the cause, prediction of auditory features, prevention of deafness, management of associated symptoms, determination of therapy, and genetic counseling. Implementing new and powerful DNA high throughput sequencing technologies is likely to happen within the next several years, and will cause a breakthrough in terms of power and cost efficiency. This ability will greatly improve DNA diagnostics. This chapter focuses on describing clinical implications of the most frequent genes including GJB2, which is responsible for more than half of cases, followed by SLC26A4, MYO15A, OTOF, CDH23, TMC1, WFS1, MYO7A, and COCH and a cost-effective stepwise diagnostic paradigm for sensorineural hearing loss.",
author = "Peter King and Ariel Grobman and Liu, {Xue Z}",
year = "2011",
month = "4",
day = "1",
language = "English",
isbn = "9781612095080",
pages = "399--410",
booktitle = "Hearing Loss: Classification, Causes and Treatment",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Clinical application of genetic testing for sensorineural hearing loss

AU - King, Peter

AU - Grobman, Ariel

AU - Liu, Xue Z

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Hearing loss (HL) is the most common sensory disorder, affecting all age groups, ethnicities, and genders. According to World Health Organization (WHO) estimates in 2005, 278 million people worldwide have moderate to profound HL in both ears. Results of the 2002 National Health Interview Survey indicate that nearly 31 million of all non-institutionalized adults (aged 18 and over) in the United States have trouble hearing. Epidemiological studies have estimated that approximately 50% of profound HL can be attributed to genetic causes. With over 60 genes implicated in nonsyndromic hearing loss, it is also an extremely heterogeneous trait. Hearing loss can be acquired or inherited and can also be either syndromic or non-syndromic. Recent progress in identifying genes responsible for hearing loss enables otolaryngologists and other clinicians to apply molecular diagnosis by genetic testing. However, the routine application of these tests is hampered by the large number of genes involved in HL and by the fact that molecular screening of these genes is often quite expensive and time consuming. Only a minority of these genes is currently included in genetic diagnostics. In childhood hearing loss, early educational intervention is required in addition to medical intervention for normal development of speech and language. In addition, even severe to profound hearing loss may be restored very effectively by hearing aids or cochlear implants. Because of these features of sensorineural hearing loss (SNHL), genetic testing has exceptionally high value in the medical practice for hereditary hearing loss. Several strategies are used for genetic testing of SNHL for accurate and efficient identification of the genetic causes, and the results were used for explanation of the cause, prediction of auditory features, prevention of deafness, management of associated symptoms, determination of therapy, and genetic counseling. Implementing new and powerful DNA high throughput sequencing technologies is likely to happen within the next several years, and will cause a breakthrough in terms of power and cost efficiency. This ability will greatly improve DNA diagnostics. This chapter focuses on describing clinical implications of the most frequent genes including GJB2, which is responsible for more than half of cases, followed by SLC26A4, MYO15A, OTOF, CDH23, TMC1, WFS1, MYO7A, and COCH and a cost-effective stepwise diagnostic paradigm for sensorineural hearing loss.

AB - Hearing loss (HL) is the most common sensory disorder, affecting all age groups, ethnicities, and genders. According to World Health Organization (WHO) estimates in 2005, 278 million people worldwide have moderate to profound HL in both ears. Results of the 2002 National Health Interview Survey indicate that nearly 31 million of all non-institutionalized adults (aged 18 and over) in the United States have trouble hearing. Epidemiological studies have estimated that approximately 50% of profound HL can be attributed to genetic causes. With over 60 genes implicated in nonsyndromic hearing loss, it is also an extremely heterogeneous trait. Hearing loss can be acquired or inherited and can also be either syndromic or non-syndromic. Recent progress in identifying genes responsible for hearing loss enables otolaryngologists and other clinicians to apply molecular diagnosis by genetic testing. However, the routine application of these tests is hampered by the large number of genes involved in HL and by the fact that molecular screening of these genes is often quite expensive and time consuming. Only a minority of these genes is currently included in genetic diagnostics. In childhood hearing loss, early educational intervention is required in addition to medical intervention for normal development of speech and language. In addition, even severe to profound hearing loss may be restored very effectively by hearing aids or cochlear implants. Because of these features of sensorineural hearing loss (SNHL), genetic testing has exceptionally high value in the medical practice for hereditary hearing loss. Several strategies are used for genetic testing of SNHL for accurate and efficient identification of the genetic causes, and the results were used for explanation of the cause, prediction of auditory features, prevention of deafness, management of associated symptoms, determination of therapy, and genetic counseling. Implementing new and powerful DNA high throughput sequencing technologies is likely to happen within the next several years, and will cause a breakthrough in terms of power and cost efficiency. This ability will greatly improve DNA diagnostics. This chapter focuses on describing clinical implications of the most frequent genes including GJB2, which is responsible for more than half of cases, followed by SLC26A4, MYO15A, OTOF, CDH23, TMC1, WFS1, MYO7A, and COCH and a cost-effective stepwise diagnostic paradigm for sensorineural hearing loss.

UR - http://www.scopus.com/inward/record.url?scp=84895350324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895350324&partnerID=8YFLogxK

M3 - Chapter

SN - 9781612095080

SP - 399

EP - 410

BT - Hearing Loss: Classification, Causes and Treatment

PB - Nova Science Publishers, Inc.

ER -